VEGFA and atypical teratoid rhabdoid tumor: A phase II study, aiming to evaluate the efficacy of the anti-VEGF antibody bevacizumab in children with recurrent and progressive medulloblastoma, ependymoma, or the atypical teratoid rhabdoid tumor (ATRT) is recruiting (NCT01356290) (Table 4).